Research Review: 4 Secrets for Preclinical Success

April 25, 2018

A Q&A with Paul Gonzales of TD2 on the essentials for preclinical success—and what researchers should know going into every project.

Q. What makes a preclinical project successful?

You need a clear understanding of project goals, model systems and variables that could impact study outcomes, but it’s equally important to work with a team that also understands those goals and can execute strategically to ensure the best chance for success.

Q. What should researchers know going into every project? 

You should know the value of your study’s data and how it directly supports your compound’s progress toward the clinic. Each study should move your compound along its development path and take you one step closer to treating patients.

Q. What are some common mistakes that researchers make during preclinical projects?

Not identifying all the study variables can be the difference between a successful outcome and a failed study. Another common mistake is when researchers latch on to a single indication strategy; instead, maintain an open mind and let the science drive decision-making.

Q. What are some of the top challenges researchers face, and how can they overcome them?

Results from studies performed solely in the originator’s lab can be viewed suspiciously, so it’s critical to have independent third-party confirmation of experimental data. Also, data reproduction is challenging, so work with a team that has a track record of ensuring uncompromised, reproducible data.

As TD2 client, you’ll get exclusive access to an integrated and diverse suite of preclinical tools (in vitro, in vivo and specialized PDx models) that can provide strong experimental support for a well-defined clinical and regulatory strategy, including bioanalytical and ADME support services.

Enhancing Immuno-Oncology Research: Top 5 Essential Flow Cytometry Assays

March 19, 2024

Flow cytometry is a powerful technique used in immuno-oncology research to analyze the physical and chemical characteristics of particles in a fluid ...

Read more +

The Significance of Preclinical Evaluation in CAR T-cell Therapy for Solid and Hematologic Tumors

January 30, 2024

Cell therapy has emerged as a promising approach in the field of cancer treatment, and chimeric antigen receptor (CAR) T-cell therapy has shown ...

Read more +

Advancing Preclinical Cancer Research Through Metabolomics: Key Strategies for Biomarker Identification and Drug-Target Analysis in Immuno-Oncology

January 18, 2024

The dynamic field of cancer research is continually evolving, driven by the pursuit of deeper understanding and novel therapeutic strategies against ...

Read more +

Orthotopic vs. Subcutaneous: Unpacking the Strengths and Limitations of Tumor Model Implantation Sites

October 24, 2023

The scientific community has long appreciated the importance of in vivo tumor models for understanding cancer biology and testing therapeutic ...

Read more +

Get Started

Contact Us Today!

If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.